Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities

Process Scale Purification of Antibodies

Volumn , Issue , 2008, Pages 1-23

  Kelley, Brian ^a   Blank, Greg ^a   Lee, Ann ^a  

^a GENENTECH INC   (United States)

Author keywords

Downstream processing of monoclonal antibodies; Process Analytical Technology (PAT) and mAb purification; Purification process development current approaches

Indexed keywords

EID: 84890727968     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470444894.ch1     Document Type: Chapter

References (34)

1. Siegel, J. (2005). The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy 25, 78 S-84 S.
2. Johnston, A., Adcock, W. (2000). The use of chromatography to manufacture purer and safer plasma products. Biotechnology and Genetic Engineering Reviews 17 , 37-70.
3. Lebing, W., Remington, K.M., Schreiner, C., Paul, H.-I. (2003). Properties of a new intravenous immunoglobulin (IGIV - C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 84, 193-201.
4. Fahrner, R.L., Knudsen, H.L., Basey, C.D., Galan, W., Feuerhelm, D., Vanderlaan, M., Blank, G.S. (2001). Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes. Biotechnology and Genetic Engineering Reviews 18, 301-327.
5. Shukla, A., Hubbard, B., Tressel, T., Guhan, S., Low, D. (2007). Downstream processing of monoclonal antibodies-Application of platform approaches. Journal of Chromatography B 848, 28-39.
6. Ghose, S., Hubbard, B., Cramer, S.M. (2007). Binding capacity differences for antibodies and Fc - fusion proteins on protein A chromatographic materials. Biotechnology and Bioengineering 96, 768-779.
7. Kelley, B.D., Switzer, M., Bastek, P., Kramarczyk, J., Molnar, K., Yu, T., Coffman, J. (2008). High - throughput screening of chromatographic separations. 4. Ion - exchange. Biotechnology and Bioengineering 100, 950-963.
8. Kelley, B.D., Tobler, S.A., Brown, P., Coffman, J., Godavarti, R., Iskra, T., Switzer, M. , Vunnum, S. (2008). Weak partitioning chromatography for anion exchange purification of monoclonal Antibodies. Biotechnology and Bioengineering 101, 553-566.
9. Low, D., O'Leary, R., Pujar, N.S. (2007). Future of antibody purification. Journal of Chromatography B 848, 48-63.
10. Ladisch, M.R., Kohlmann, K.L. (1992). Recombinant human insulin. Biotechnology Progress 8, 469-478.
11. O ' Leary, R. (2003). Post - approval changes: A necessary evil in the product lifecycle. Recovery of Biological Products XI, Banff, Alberta, Canada, 2003.
12. Kelley, B.D., Tannatt, M., Magnusson, R., Hagelberg, S., Booth J. (2004). D evelopment and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII. Biotechnology and Bioengineering 87, 400-412.
13. Kempken, R., Preissmann, A., Berthold, W. (1995). Assessment of a disc stack centrifuge for use in mammalian cell separation. Biotechnology and Bioengineering 46 , 132-138.
14. Bender, J., Wolk, B. (1998). Putting a spin on CHO harvest: Centrifuge technology development. ACS Meeting, Boston, MA, 1998.
15. Shpritzer, R., Vicik, S., Orlando, S., Acharya, H., Coffman, J.L. (2006). Calcium phosphate flocculation of antibody - producing mammalian cells at pilot scale. Abstracts of Papers, 232nd ACS Meeting, San Francisco, CA, 2006.
16. Yigzaw, Y., Piper, R., Tran, M., Shukla, A.A. (2006). Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnology Progress 22, 288-296.
17. Roque, A.C.A., Silva, C.S.O., Taipa, M.A. (2007). Affinity - based methodologies and ligands for antibody purification: Advances and perspectives. Journal of Chromatography A 1160, 44-55.
18. Zhou, J.X., Tressel, T. (2006). Basic concepts in Q membrane chromatography for large - scale antibody production. Biotechnology Progress 22, 341-349.
19. Luan, Y.- T. (2006). Defined medium development for high yielding mammalian cell culture processes. BioProcess International Conference & Exhibition: IBC ' s 7th International Cell Culture & Upstream Processing, San Francisco, CA, 2006.
20. Jagschies, G., Grönberg, A., Björkman, T., Lacki, K., Johansson, H.J. (2006). Technical and economical evaluation of downstream processing options for monoclonal antibody (Mab) production. BioPharm International 19 (suppl.), 2-8.
21. Kelley, B.D. (2007). Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnology Progress 23, 995-1008.
22. Hagel, L., Jagschies, G., Sofer, G. (2007). Production scenarios. In Hagel, L. , Jagschies, G., Sofer, G. (eds.) H andbook of Process Chromatography: Development, Manufacturing, Validation and Economics, 2nd eds., Academic Press, London, pp. 22-39.
23. Brorson, K., Brown, J., Hamilton, E., Stein, K.E. (2003). Identification of protein A media performance attributes that can be monitored as surrogates for retrovirus clearance during extended re - use. Journal of Chromatography A 989, 155-163.
24. Blank, G.S. (2006). Modular validation for BLA process ranges. WCBP CMC Strategy Forum, Bethesda, MD, July 20.
25. FDA (2006). International Committee on Harmonisation. Q8: Pharmaceutical Development.
26. Shepherd, A.J., Wilson, N.J., Smith, K.T. (2003). Characterisation of endogenous retrovirus in rodent cell lines used for production of biologicals. Biologicals 31 , 251-260.
27. FDA (1999). International Committee on Harmonisation. Q5a: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
28. FDA Center for Biologics Evaluation and Research (1997). Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. FDA Department of Health and Human Services, Rockville, MD.
29. Brorson, K., Krejci, S., Lee, K., Hamilton, E., Stein, K., Xu. Y. (2003). Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnology and Bioengineering 82 , 321-329.
30. Breece, T., Mallon, E., Giese, G., Persson, J., Gorrell, J. (2006). Evaluation of chromatography media for dual sourcing using a platform technology. Recovery of Biological Products XII, Litchfield, AZ, 2006.
31. FDA Center for Drugs and Biologics (1984). Points to Consider the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology. FDA Department of Health and Human Services, Rockville, MD.
32. Griffiths, E. (1997). WHO Expert Committee on Biological Standardization: Highlights of the meeting of October 1996. Biologicals 25, 359-362.
33. Anon (2004). Clearer paradigm sought for biopharmaceutical specifications. The Gold Sheet 38, 9-31.
34. FDA Center for Drug Evaluation and Research (2004). Pat-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA Department of Health and Human Services, Rockville, MD.